Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Acadia Pharmaceuticals (ACAD)

Nasdaq Health Care Pharmaceuticals S&P SmallCap 600
$21.23
-0.01 (-0.05%)
Close of Nov 06, 2026 · end-of-day data
Source: Acadia Pharmaceuticals's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 05, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$17.33M$124.90M$223.81M$339.08M$441.75M$484.14M$517.24M$726.44M$957.80M$1.07B
Cost of revenue$3.08M$9.08M$12.38M$11.34M$10.21M$19.14M$10.17M$41.64M$81.84M$89.00M
Gross profit$14.25M$115.82M$211.43M$327.73M$431.54M$473.30M$507.07M$684.80M$875.96M$982.51M
Research & development$99.28M$149.19M$187.16M$240.38M$319.13M$239.41M$361.57M$351.62M$303.25M$328.80M
Selling, general & admin$186.46M$255.06M$265.76M$325.64M$388.66M$396.03M$369.09M$406.56M$488.43M$548.89M
Operating income-$272.81M-$292.41M-$247.44M-$246.54M-$286.59M-$170.44M-$223.60M-$73.38M$230.79M$104.81M
Pre-tax income-$270.05M-$288.28M-$243.94M-$234.38M-$280.97M-$167.52M-$213.44M-$51.04M$258.07M$138.90M
Income tax$1.34M$1.12M$1.26M$876.00K$611.00K$351.00K$2.53M$10.25M$31.62M-$252.10M
Net income-$271.39M-$289.40M-$245.19M-$235.26M-$281.58M-$167.87M-$215.97M-$61.29M$226.45M$391.00M
EBITDA-$271.97M-$291.17M-$245.91M-$245.26M-$285.13M-$168.20M-$221.57M-$71.92M$231.71M$105.68M
EPS (basic)$-2.34$-2.36$-1.94$-1.60$-1.79$-1.05$-1.34$-0.37$1.37$2.32
EPS (diluted)$-2.34$-2.36$-1.94$-1.60$-1.79$-1.05$-1.34$-0.37$1.36$2.30
Diluted shares115.86M122.60M126.58M147.20M157.33K160.49K161.68M163.82M166.36M169.92M
Gross margin82.2%92.7%94.5%96.7%97.7%97.8%98.0%94.3%91.5%91.7%
Operating margin-1574.1%-234.1%-110.6%-72.7%-64.9%-35.2%-43.2%-10.1%24.1%9.8%
Net margin-1565.9%-231.7%-109.6%-69.4%-63.7%-34.7%-41.8%-8.4%23.6%36.5%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$163.62M$69.42M$134.76M$189.68M$326.03M$147.44M$114.85M$188.66M$319.59M$177.69M
Short-term investments$365.42M$271.92M$338.76M$507.75M$305.93M$373.27M$301.98M$250.21M$436.40M$641.99M
Receivables$5.90M$17.34M$26.09M$35.78M$48.25M$64.37M$62.20M$98.27M$98.74M$121.46M
Inventory$4.17M$5.25M$4.07M$6.34M$9.68M$14.10M$11.56M$40.45M$91.69M$111.37M
Total current assets$547.90M$373.48M$526.11M$760.25M$717.62M$617.82M$507.94M$616.12M$938.32M$1.06B
Total assets$561.15M$384.51M$540.20M$783.18M$782.62M$700.12M$587.81M$748.96M$1.19B$1.56B
Total current liabilities$42.59M$49.03M$59.56M$74.83M$105.97M$96.07M$125.63M$254.25M$394.87M$277.11M
Total liabilities$42.74M$49.22M$61.12M$84.05M$155.61M$159.23M$187.40M$317.20M$454.96M$336.81M
Shareholders' equity$518.41M$335.29M$479.08M$699.13M$627.01M$540.89M$400.41M$431.75M$732.79M$1.23B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$208.41M-$217.76M-$167.47M-$151.13M-$136.17M-$125.66M-$114.03M$16.70M$157.72M$109.84M
Capital expenditures$1.51M$812.00K$2.10M$1.13M$7.59M$1.12M$0$50.00K$523.00K$4.69M
Free cash flow-$209.91M-$218.57M-$169.57M-$152.26M-$143.75M-$126.78M-$114.03M$16.65M$157.20M$105.15M
Investing cash flow-$261.92M$92.47M-$71.49M-$165.84M$192.51M-$71.10M$73.24M$32.00M-$30.54M-$302.56M
Financing cash flow$533.81M$31.19M$306.65M$371.85M$81.00M$18.16M$8.20M$25.13M$6.84M$49.88M
Stock-based compensation$55.27M$75.53M$81.56M$82.27M$84.42M$63.62M$68.20M$66.42M$67.05M$52.13M
Depreciation & amortization$843.00K$1.24M$1.53M$1.29M$1.46M$2.24M$2.03M$1.46M$920.00K$871.00K

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.